Home
News & Events
Leadership & Mission
Technology
Contact

Menu

Product Candidates Pipeline

Navrogen provides Research and Development services for its business partners to advance clinical product candidates for the treatment of various cancers. Current pipeline is shown below.

navrogen pipeline

NAVROGEN INC. AND LONZA SIGN AGREEMENT TO USE LONZA’S GS GENE EXPRESSION SYSTEM^® FOR NAVROGEN’S ANTI-HIO TARGETING AGENTS

Philadelphia, PA (USA) and Basel (CH), 20 November 2019 -- Navrogen Inc. and Lonza Pharma & Biotech announced today that they have entered a licensing agreement for the production of Navrogen's biotherapeutics using Lonza’s GS Xceed Expression System. read more→

Navrogen's Mission

To be an industry leader in the area of humoral immuno oncology (HIO), a process whereby tumors produce factors that suppress the beneficial effects of patient’s immune systems against cancer as well as the therapeutic effects of antibody-based anti-cancer therapies.

NAVROGEN ENTERS INTO CRADA WITH THE U.S. NATIONAL CANCER INSTITUTE TO DEVELOP AGENTS TO OVERCOME TUMOR-MEDIATED IMMUNO-SUPPRESSION

Philadelphia, PA, October 1, 2019 -- Navrogen, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI). The CRADA is focused on advancing antibody-based experimental medicines to targets associated with tumor-mediated immuno-suppression. read more→

NAVROGEN ANNOUNCES THE CLOSING OF $3.2M FUNDING TO SUPPORT ITS HUMORAL IMMUNO-ONCOLOGY PLATFORM DISCOVERY TECHNOLOGIES AND PRECLINICAL PIPELINE

Philadelphia, PA, September 17, 2019 -- Navrogen, Inc. announced today that it has raised $3.2M in convertible note financing to support its operations, Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities. The financing was led by Ben Franklin Technology Partners of South Eastern Pennsylvania and a number of private investors. read more→

Luigi Grasso

Luigi Grasso, Ph.D. is the Sr Vice President, Chief Scientific Officer and co-founder of Navrogen Inc. Prior to co-founding Navrogen, he was Vice President, CSO and co-founder of Morphotek Inc., a private biopharmaceutical company specializing in the development of antibody-based therapies for cancer, which was acquired by Eisai, Co. Ltd. in 2007. From 2007 to 2018, he remained at Morphotek as VP and CSO and oversaw the global R&D of antibody and next gen antibody-based products for the treatment of various cancer indications. read more→

Nicholas C. Nicolaides

Nicholas C. Nicolaides, Ph.D. is the President, Chief Executive Officer and co-founder of Navrogen™ Inc., a biopharmaceutical company developing targeted therapies for the treatment of cancer and immune-related disorders. From 2000 to 2018 he was the President, Chief Executive Officer and co-founder of Morphotek^® Inc., a biopharmaceutical company specializing in the development of first-in-class antibody based products for the treatment of cancer, inflammatory and infectious diseases. read more→

“Na vro” (να βρω) is Greek for “to find”

Did you know...

We at Navrogen are committed to finding solutions and applying them to next-generation biologicals. Finding these solutions is at the core our mission.

Copyright © 2019 Navrogen - All Rights Reserved

A SiteOrigin Theme